Status:
COMPLETED
Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome
Lead Sponsor:
Ain Shams University
Conditions:
Nephrotic Syndrome
Sodium-Glucose Transporter 2 Inhibitors
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Conducted as a randomized controlled clinical trial, this study aims to assess the potential benefits of incorporating dapagliflozin, an SGLT-2 inhibitor, into the treatment regimen of patients diagno...
Eligibility Criteria
Inclusion
- eGFR \> 25 mL/min/1.73m2
- Evidence of primary nephrotic syndrome by renal biopsy
- Non-diabetic kidney disease
Exclusion
- Nephrotic syndrome secondary to lupus nephritis, AAV, amyloidosis, or secondary membranous nephropathy
- Hepatic impairment \[AST or ALT \>3 times ULN or total bilirubin \>2 times the ULN\] at the time of enrolment
- Pregnant or breast-feeding females
Key Trial Info
Start Date :
August 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT06026787
Start Date
August 1 2022
End Date
August 1 2023
Last Update
September 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ain Shams University Hospitals
Cairo, Egypt